48 citations,
June 2008 in “Drug Discovery Today: Disease Mechanisms” Hair follicles offer promising targets for delivering drugs to treat hair and skin conditions.
32 citations,
January 2017 in “Orphanet journal of rare diseases” FOXN1 gene mutations cause a rare, severe immune disease treatable with cell or tissue transplants.
February 2024 in “Sohag Medical Journal” Various local treatments for alopecia areata show promise, but individualized plans and more research are needed.
32 citations,
August 2020 in “Cytokine” Type I interferons play a key role in the development of various skin diseases.
56 citations,
February 2010 in “PLOS ONE” Blocking Wnt signaling in young mice causes thymus shrinkage and cell loss, but recovery is possible when the block is removed.
9 citations,
February 2022 in “Nature communications” Rare changes in the KRT82 gene are linked to a higher risk of Alopecia Areata.
2 citations,
October 2022 in “Journal of Biomedical Science” Stem cells and their secretions could potentially treat stress-induced hair loss, but more human trials are needed.
4 citations,
January 2023 in “Skin health and disease” Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.
2 citations,
September 2022 in “Frontiers in Immunology” T-regulatory cells are important for skin health and can affect hair growth and reduce skin inflammation.
116 citations,
April 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
May 2022 in “Liver transplantation” The document explains how the immune system reacts to organ transplants and the treatments used to prevent rejection.
6 citations,
May 2019 in “American journal of transplantation” UV light helped human hair transplants survive in mice without broad immunosuppression.
139 citations,
February 2010 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Transplant success has improved with better immunosuppressive drugs and donor matching.
5 citations,
October 2018 in “American Journal of Clinical Dermatology” Skin problems are common after stem cell transplants, and early treatment by dermatologists can improve patient outcomes.
44 citations,
April 2015 in “Journal of the American Academy of Dermatology” Combining diphenylcyclopropenone with anthralin is more effective for hair regrowth in alopecia areata than using diphenylcyclopropenone alone, but may cause more side effects.
69 citations,
July 2002 in “Clinical and Experimental Dermatology” Alopecia areata is influenced by genetics and immune system factors, and better understanding could improve treatments.
11 citations,
June 2019 in “Journal of dermatology” New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.
10 citations,
May 2019 in “Internal Medicine” Myasthenia gravis can affect both motor and non-motor systems due to immune system issues.
6 citations,
May 2013 in “The Journal of Dermatology” Autoimmune reactions may cause both alopecia areata and HAM.
4 citations,
September 2020 in “JAAD case reports” Permanent hair dye may cause total hair loss.
3 citations,
January 2023 in “Skin appendage disorders” Some people with a history of autoimmune hair loss experienced worsening symptoms after COVID-19 vaccination.
Some vaccines, like the hepatitis B vaccine, might be linked to the hair loss condition Alopecia Areata, but more research is needed.
6 citations,
September 2015 in “Journal of theoretical biology” The model showed that immune system guardians and the cytokine interferon-γ are key in alopecia areata progression.
1 citations,
November 2017 in “Dermatologic therapy” JAK inhibitors show promise as a future treatment for hair loss.
1 citations,
October 2013 in “The Journal of Dermatology” Hair loss in a drug reaction case involved both a common shedding phase and an immune attack on hair follicle stem cells.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
January 2019 in “Przegląd Dermatologiczny” An 87-year-old woman was diagnosed with type 3 autoimmune polyendocrine syndrome and had multiple autoimmune issues.
157 citations,
February 2016 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
90 citations,
July 2008 in “Dermatologic therapy” Lichen planopilaris is a chronic, scarring hair loss condition with no definitive cure, requiring accurate diagnosis and treatment to manage symptoms.
66 citations,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.